Inspira Technologies Oxy (IINN) said Friday that it is preparing to ramp up production of its Inspira ART100 respiratory device amid the recent outbreak of human metapneumovirus, or hMPV, in China.
The company said it is in talks with providers in affected regions to evaluate demand for the device and is working with suppliers to secure the components. Inspira also said it will coordinate with health authorities and "adjust its plans based on the evolving situation."
Shares of Inspira Technologies Oxy were up 13% premarket.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.